Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel-group, 24-week Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension

NCT02021292 is registered in ClinicalTrials.gov with Actelion as lead sponsor.

NCT NCT02021292
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02021292 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel-group, 24-week Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension
Lead sponsor
Actelion
Phase
Phase 2
Overall status
Completed
Start date
August 20, 2014
Completion date
September 28, 2016
Enrollment
80 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

chronic thromboembolic pulmonary hypertension